Kristine Ball
Director/Board Member bei ATRECA, INC.
Vermögen: - $ am 31.03.2024
Profil
Kristine McClintock Ball is currently the Chief Executive Officer at Antiva Biosciences, Inc. and also holds the position of Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She is an Independent Director at Atreca, Inc. and a Director at the National Kidney Foundation of Northern California.
Previously, Dr. Ball served as the Chief Executive Officer & Director at Soteria Biotherapeutics, Inc. She was an Independent Director at Forty Seven, Inc. from 2018 to 2020.
She also worked as a Senior Manager at Ernst & Young LLP from 1998 to 2000 and as the Vice President-Finance at Exelixis, Inc. from 2000 to 2005.
Additionally, she held the position of CFO, Senior VP-Administration & Finance at KAI Pharmaceuticals, Inc. From 2017 to 2020, Dr. Ball served as the Chief Financial Officer & SVP-Corporate Strategy at Menlo Therapeutics, Inc. She was also the Chief Financial Officer & Senior Vice President at Relypsa, Inc. from 2012 to 2016.
Dr. Ball completed her undergraduate degree at Babson College.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Kristine Ball
Unternehmen | Position | Beginn |
---|---|---|
ATRECA, INC. | Director/Board Member | 20.05.2020 |
Ehemalige bekannte Positionen von Kristine Ball
Unternehmen | Position | Ende |
---|---|---|
FORTY SEVEN, INC. | Director/Board Member | 07.04.2020 |
VYNE THERAPEUTICS INC. | Director of Finance/CFO | 01.03.2020 |
RELYPSA INC | Director of Finance/CFO | 01.01.2016 |
EXELIXIS, INC. | Director of Finance/CFO | 01.01.2005 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2000 |
Ausbildung von Kristine Ball
Babson College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
EXELIXIS, INC. | Health Technology |
ATRECA, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
KAI Pharmaceuticals, Inc.
KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Relypsa, Inc.
Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Menlo Therapeutics, Inc.
Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Forty Seven, Inc.
Forty Seven, Inc. Pharmaceuticals: MajorHealth Technology Forty Seven, Inc. develops therapies that target cancer immune evasion pathways. It develops Hu5F9-G4, a monoclonal antibody against human CD47 that potentially has applications spanning multiple tumor types and treatment modalities. The company was founded by Irving L. Weissman, Ravi Majeti, Mark Chao and Jens-Peter Volkmer in 2014 and is headquartered in Menlo Park, CA. | Health Technology |